| Open Document File Size: 96,65 KBShare Result on Facebook
Company UCB Inc. / Introduction UCB Inc. / ITT / / Country United States / / Event FDA Phase / / IndustryTerm machinery / final product / administered product / mg/mL products / age / manufacturing process / / MedicalCondition uncomplicated skin manifestations / Pulmonary / diseases / skin manifestations / same diseases / Seasonal and perennial allergic rhinitis / chronic idiopathic urticaria / / Organization FDA / Advisory Committee / / Person Badrul A. Chowdhury / / Position Physician / Director Summary Review NDA Number Division / representative / Director / Division of Pulmonary and Allergy Products / / Product Xyzal / Xyzal 5 mg / Controls Xyzal 5 mg / Xyzal solution / Xyzal oral / Xyzal tablet / Controls Xyzal / / RadioStation Xyzal 1.25 QD AM / / Technology simulation / /
SocialTag |